1. Scrip

Generex's oral insulin submitted for approval in Syria

 
• By John Davis

[C#200000856:Generex] Biotechnologyhas submitted a marketing application in Syria for its oral insulin product, [C#200000856:Generex] Oral-lyn, and expects approval before the end of next year. [C#200000856:Generex]'s product uses its RapidMist device to deliver a liquid spray of insulin to the lining of the mouth. The product is available in Ecuador, and has been approved for sale in India. Phase III clinical trials are under way in the US and elsewhere.

Generex Biotechnologyhas submitted a marketing application in Syria for its oral insulin product, Generex Oral-lyn, and expects approval before the end of next year. Generex's product uses its RapidMist device to deliver a liquid spray of insulin to the lining of the mouth. The product is available in Ecuador, and has been approved for sale in India. Phase III clinical trials are under way in the US and elsewhere.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.